Countries are not doing enough to contain monkeypox outbreak, epidemiologist says

Countries are not doing enough to contain monkeypox outbreak, epidemiologist says


There are grave concerns that the U.S. and other countries are not doing enough to contain monkeypox from becoming a large scale global outbreak, according to an infectious disease epidemiologist.

Over the weekend, the World Health Organization activated its highest alert level for the virus, labeling monkeypox a public health emergency of international concern.

The rare designation means the WHO now views the outbreak as a significant enough threat to global health that a coordinated international response is needed to prevent the virus from potentially escalating into a pandemic. 

“This is a unique outbreak where we know this virus, but it’s causing a very large outbreak in a number of countries around the world. In fact, if we look at case counts, United States is kind of trailing behind Spain in the number of cases,” Dr. Syra Madad, senior director of the special pathogens program at New York City Health + Hospitals, told CNBC’s “Squawk Box Asia” on Monday.

“It’s not an outbreak to take lightly. What is a really big concern is that it becomes an established virus in the United States, as well as in other countries that this virus is not endemic to,” she added.

Madad said “it is really unacceptable,” especially in the wake of the Covid pandemic, for countries to be struggling to contain the spread of monkeypox.

“Having all the lessons learned with Covid-19, we should not be dealing with an outbreak of this scale and are not doing enough to ensure that this does not become endemic,” she added.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Although the WHO declaration does not impose requirements on national governments, it serves as an urgent call for action.

Growing virus cases

The U.S. Centers for Disease Control and Prevention said monkeypox can spread through respiratory droplets after prolonged face-to-face interaction or intimate physical contact. The virus can also spread through contact with bodily fluids, skin lesions as well as contaminated items like bedsheets and clothing.

More than 16,000 cases of monkeypox have been reported across more than 70 countries so far this year, and the number of confirmed infections rose 77% from late June through early July, according to WHO data. 

Madad said while men who have sex with men are currently at highest risk of infection, the virus is starting to spread to a wider community.

“For example, in the United States, two children contracted monkeypox through household transmission of someone that has monkeypox. We know those cases may start to increase over a period of time as more transmissions happening in the community,” she said.

On Monday, the WHO warned against complacency in containing the outbreak, saying there is no guarantee that the virus will continue to spread within specific communities.

While cases have so far been concentrated primarily within gay and bisexual communities, the U.N. health agency said there is little evidence to suggest that the disease will remain confined to those groups.

Rather, their early detection could be a harbinger of a wider outbreak.

U.S. vaccine challenges

Madad said the best way to cut chains of transmission is to vaccinate people who are at risk and may have been exposed to monkeypox. She noted, however, access to vaccines is an issue, especially in the U.S.

On Friday, a senior White House official said President Joe Biden is considering declaring a public health emergency in response to the growing monkeypox outbreak. Dr. Ashish Jha, the White House Covid response coordinator, said the administration is looking at how a public health emergency declaration might bolster the U.S. response to the outbreak.

The U.S. has reported more than 2,500 monkeypox cases so far across 44 states, Washington, D.C., and Puerto Rico, according to the CDC.

“The vaccines are continuing to be released to territories, cities and states. By the end of this year, we’re going to have about 1.6 million by the end of 2023 or mid-2023 — we’re going to  have millions of doses,” Madad said.

“But the problem here is that it’s just not happening enough,” she added as demand is currently outstripping supply. “We really need to get ahead of this epidemic.”

—  CNBC’s Spencer Kimball contributed to the report.



Source

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
Health

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday.  […]

Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Health

Pfizer tops estimates, raises profit guidance even as sales fall

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Read More